11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

Futibatinib is recommended as an option for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least one line of systemic treatment. 

Futibatinib is only recommended if Taiho Pharmaceutical provides it according to the commercial arrangement.

Read NICE technology appraisal guidance